T. Bucsics

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
T Bucsics, T. Bucsics, Theresa A. Bucsics, Theresa Bucsics
Publication record
115 papers · 3,424 citations · H-index 27

PAPERS

LBP-028 Variceal hemorrhage outcomes are worse in patients with prior decompensating events. Systematic review with individual patient data meta-analysis
20250 citationsauthor #10
TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.
202379 citationsauthor #5
Spontaneous portosystemic shunts (SPSS) regress after transjugular intrahepatic portosystemic shunt (TIPS) implantation
20230 citationsauthor #1
Dynamics of liver stiffness measurements provide incremental prognostic information in advanced chronic liver disease
20230 citationsauthor #10
TIPS increases muscle mass in patients with decompensated cirrhosis
20230 citationsauthor #1
Covered TIPS reduces the risk of further decompensation: results from an individual patient data meta-analysis of 3924 patients with cirrhosis
20221 citationsauthor #5
Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
202130 citationsauthor #9
The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes
202118 citationsauthor #11
The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices
20210 citationsauthor #7
The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices.
202120 citationsauthor #10
Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites
202115 citationsauthor #8
Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis
202110 citationsauthor #1
Non-invasive monitoring of liver disease regression in patients with advanced chronic liver disease after sustained virologic response to INF-free therapies
20204 citationsauthor #9
Impact of beta blocker therapy on systemic inflammation stratified by hepatic venous pressure gradient response
20200 citationsauthor #11
Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis
202053 citationsauthor #8
Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes
202073 citationsauthor #11
Beta blocker therapy seems to reduce systemic inflammation in cirrhotic patients with portal hypertension - a paired HVPG study
20200 citationsauthor #8
Incidence and outcome of acute-on-chronic liver failure in a large retrospective single-center cohort
20200 citationsauthor #6
Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria
20206 citationsauthor #9
Impact of genetic variants on liver disease regression in HCV patients with advanced chronic liver disease who achieved SVR to IFN-free therapies
20200 citationsauthor #9
Impact of genetic variants on regression of portal hypertension and clinical outcomes in ACLD patients after SVR
20200 citationsauthor #8
Use of human albumin in a large “real-life” single-center cohort of patients with decompensated advanced chronic liver disease
20200 citationsauthor #6
Distinct features of the portalhypertensive syndrome in patients with advanced chronic liver disease due to non-alcoholic steatohepatitis
20200 citationsauthor #14
Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease.
20200 citationsauthor #6
Humoral biomarkers of hemodynamic derangement in distinct stages of portal hypertension
20200 citationsauthor #9
Non-invasive risk stratification by VCTE and VITRO after HCV eradication
20200 citationsauthor #9
Differential activation of humoral compensatory mechanisms in distinct stages of portal hypertension
20200 citationsauthor #10
Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
202027 citationsauthor #5
Vitamin A deficiency is associated with disease severity and portal hypertension in patients with advanced chronic liver disease
20200 citationsauthor #7
Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
202018 citationsauthor #7
Clinical course of porto-sinusoidal vascular disease (PSVD) is distinct from idiopathic non-cirrhotic portal hypertension (INCPH).
202043 citationsauthor #10
Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease
202050 citationsauthor #12
Elast q - 2D shear wave liver elastography correlates well with vibration controlled transcient elastography in patients with different etiologies of chronic liver disease
20200 citationsauthor #6
Point shear wave elastography by ElastPQ accurately stages hepatic fibrosis in patients with NAFLD: A prospective, multicentric study
20190 citationsauthor #2
Reliability criteria for controlled attenuation parameter (CAP) for assessing hepatic steatosis using transient elastography
20190 citationsauthor #8
PS-067-Increasing incidence of HCV-GT2 as well as reinfections within the ongoing epidemic of acute HCV infections among MSM in Central Europe
20190 citationsauthor #5
The impact of hepatic steatosis on portal hypertension
201918 citationsauthor #4
Transjugular intrahepatic portosystemic shunt implantation improves renal function in patients with ascites
20190 citationsauthor #1
Elastography-based screening for esophageal varices in patients with advanced chronic liver disease
201959 citationsauthor #3
Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites
20198 citationsauthor #6
SAT-117-Enhanced liver fibrosis score is an accurate non-invasive predictor of clinically significant and high-risk portal hypertension
20190 citationsauthor #5
Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
201971 citationsauthor #5
Intraperitoneal activation of the coagulation system via tissue factor-exposing extracellular vesicles and enhanced fibrinolysis in patients with advanced chronic liver disease and ascites
20190 citationsauthor #5
SAT-114-Impact of farnesoid X receptor polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
20190 citationsauthor #6
Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication
201913 citationsauthor #3
Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
20190 citationsauthor #4
Detection of Various Microplastics in Human Stool
20191,261 citationsauthor #4
SAT-276-Point shear wave elastography by ElastPQ accurately stages hepatic fibrosis in patients with NAFLD: A prospective, multicentric study
20190 citationsauthor #6
Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
201913 citationsauthor #6
Impact of farnesoid X receptor (FXR) polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
20190 citationsauthor #6
Prevalence of non-alcoholic fatty liver disease (NAFLD) among HIV+ individuals in Vienna
20190 citationsauthor #7
Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
20198 citationsauthor #7
High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients
201925 citationsauthor #3
PS-021-The development of portosystemic shunts depends on liver dysfunction rather than on PlGF-driven neoangiogenesis
20190 citationsauthor #6
Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
201923 citationsauthor #4
ePTFE‐TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis
201842 citationsauthor #1
Outcome after the use of SX-ELLA Danis bleeding stents for refractory variceal bleeding- a Vienna Multicenter Experience
20180 citationsauthor #11
The impact of hepatic steatosis on portal hypertension
20180 citationsauthor #4
Liver disease in adults with α1-antitrypsin deficiency
201824 citationsauthor #2
Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding – A two decades experience
201825 citationsauthor #1
The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites
20180 citationsauthor #7
Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
201843 citationsauthor #6
Controlled attenuation parameter (CAP®) does not predict hepatic decompensation in patients with compensated advanced chronic liver disease
20183 citationsauthor #5
Small Esophageal Varices in Patients with Cirrhosis—Should We Treat Them?
201817 citationsauthor #2
Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function
201847 citationsauthor #4
Impact of SVR to IFN-free DAA regimens on steatosis in HIV/HCV coinfected patients
20181 citationsauthor #3
Epidemiological trends of HBV and HDV coinfection among HIV+ patients
20180 citationsauthor #4
Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding
201853 citationsauthor #4
Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis.
201812 citationsauthor #1
Adherence to quality criteria improves concordance between transient elastography and ElastPQ for liver stiffness assessment-A multicenter retrospective study.
201834 citationsauthor #8
The impact of thyroid hormones on patients with hepatocellular carcinoma
201728 citationsauthor #5
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III)
2017130 citationsauthor #5
Von Willebrand factor antigen predicts portal hypertensive bleeding, infections, and survival, independently of portal hypertension severity
20170 citationsauthor #3
Bacterial infections in cirrhosis – a retrospective analysis updating on microbiology and resistance rates
20170 citationsauthor #1
Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice.
201734 citationsauthor #1
Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices
201721 citationsauthor #3
Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
201720 citationsauthor #3
Anticoagulation in non-malignant portal vein thrombosis is associated with improved hepatic function
20170 citationsauthor #4
Outcome after SX-ELLA Danis bleeding stent implantation for refractory variceal bleeding – a Vienna Multicenter Experience
20170 citationsauthor #10
The role of TIPS in the management of liver transplant candidates
201728 citationsauthor #3
Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
201711 citationsauthor #2
Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome
201797 citationsauthor #1
Liver fibrosis assessment and treatment initiation within a systematic screening program among HIV/HIV-coinfected patients
20170 citationsauthor #3
Interferon‐free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease
201789 citationsauthor #7
Outcome and survival after acute variceal bleeding in patients with liver cirrhosis
20170 citationsauthor #6
ePTFE-TIPS versus repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis
20172 citationsauthor #1
Interferon-Free Daa Regimens Decrease Portal Pressure and Halt Histological Necroinflammation in HIV/HCV coinfected Patients
20161 citationsauthor #5
Non-selective beta-blocker treatment does not impact on kidney function in patients on primary and secondary prophylaxis of variceal bleeding
20160 citationsauthor #3
The trigger matters – outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites
20169 citationsauthor #1
Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease
201641 citationsauthor #6
A PREDICTOR OF MORTALITY IN RENAL DYSFUNCTION ?
20160 citationsauthor #5
Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfected patients with advanced liver disease
20164 citationsauthor #5
Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP).
201619 citationsauthor #1
The role of TIPS in the management of liver transplant candidates
20163 citationsauthor #5
Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease
201619 citationsauthor #4
Interferon-Free Treatment with Sofosbuvir Plus Daclatasvir Achieves Sustained Virologic Response in 100% of Difficult-To-Treat HIV/HCV-Coinfected Patients and Decreases Liver Stiffness
20160 citationsauthor #6
Effectiveness of early TIPS for the treatment of acute variceal bleeding – the Viennese experience
20160 citationsauthor #2
Concomitant NSBB treatment does not increase efficacy of EBL in primary prophylaxis but improves survival in secondary prophylaxis of variceal bleeding
20160 citationsauthor #4
Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study
201543 citationsauthor #1
Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites
2015100 citationsauthor #2

TIMELINE

2012 5 citations

2013 5 citations

2014 455 citations

2015 170 citations

2016 96 citations

2017 460 citations

2018 301 citations

2019 1,499 citations

2020 274 citations

2021 93 citations

2022 1 citations

2023 79 citations

2025 0 citations

T. Bucsics

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT